Breadcrumb

[A20-33] Belimumab (systemic lupus erythematosus in children and adolescents) - Addendum to Commission A19-94

Overview

Overview

Commission: Commission awarded on 2020-03-24 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Addendum to commission A19-94  [PDF, 260 kB] (German version) Further documents
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Contact address:to the contact form
Linked projects: [A19-94] Belimumab (SLE) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2020-05-14 Addendum to commission A19-94 (German version) 260 kBPDFdownload file

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.


At a glance

Accompanying information

Federal Joint Committee (G-BA)

2020-05-14 A G-BA decision was published.

G-BA documents on this decision

Press releases

2020-05-14 Belimumab in active systemic lupus erythematosus: added benefit for children and adolescents



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close